GLOBAL COST EFFECTIVE ANALYSIS OF APIXABAN VERSUS WARFARIN FOR THE PREVENTION OF STROKE AS A RESULT OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW

被引：0
|
作者：
Petrenchik, L. [1 ]
Hussain, N. [1 ]
Charles, P. [1 ]
Peprah, H. [1 ]
Loh, F. E. [1 ]
机构：
[1] Touro Coll Pharm, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.372
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV50
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
    Lee, Soyon
    Mullin, Rachel
    Blazawski, Jon
    Coleman, Craig I.
    PLOS ONE, 2012, 7 (10):
  • [2] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Athanasakis, Kostas
    Boubouchairopoulou, Nadia
    Karampli, Eleftheria
    Tarantilis, Filippos
    Savvari, Paraskevi
    Bilitou, Aikaterini
    Kyriopoulos, John
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) : 123 - 133
  • [3] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [4] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Kostas Athanasakis
    Nadia Boubouchairopoulou
    Eleftheria Karampli
    Filippos Tarantilis
    Paraskevi Savvari
    Aikaterini Bilitou
    John Kyriopoulos
    American Journal of Cardiovascular Drugs, 2017, 17 : 123 - 133
  • [5] Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
    Siddiqui, Muhammad U.
    Scalzitti, David
    Naeem, Zunaira
    CARDIOLOGY RESEARCH AND PRACTICE, 2019, 2019
  • [6] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [7] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [8] Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
    Kamel, Hooman
    Easton, J. Donald
    Johnston, S. Claiborne
    Kim, Anthony S.
    NEUROLOGY, 2012, 79 (14) : 1428 - 1434
  • [9] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [10] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
12345